… transformation to small cell lung cancer in EGFR mutant NSCLC patients with acquired EGFR
TKI resistance, accounting for resistance in possibly up to 3% of the patients. Interestingly, …

… setting, NSCLC patients with EGFR mutations have shown dramatic responses to EGFR TKIs.
… 132 Asian patients with EGFR mutations [67]. In a Spanish study involving 197 evaluable …

… In summary, our data on EGFR mutation status from a large German cohort of NSCLC patients
in the daily clinical practice are in agreement with data from other populations around the …

… ), such as epidermal growth factor receptor (EGFR) mutations [1–3], a fusion … EGFR
mutations in advanced NSCLC, which was the first experience to treat advanced NSCLC patients …

… of EGFR TKIs in EGFR-mutant lung cancer patients. The side-… patients with tumours
harbouring EGFR mutations, and established EGFR mutation status as the best biomarker for EGFR …

… In order to obtain a more precise estimate of EGFR mutation prevalence in NSCLC
patients and patient subgroups, we conducted this systematic review and meta-analysis. …

… receptor (EGFR)-mutation have … EGFR T790M-mutation in the majority of patients. Longitudinal
follow-up data are lacking. We retrospectively evaluated EGFR-mutated NSCLC-patients …

… In this retrospective study, we screened 5363 NSCLC patients to determine the
prevalence … EGFR mutation in Chinese lung cancer patients and their sensitivity to EGFR-TKIs. …

… More recent trials have suggested that for advanced NSCLC patients with EGFR mutant
tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. …

… testing for EGFR mutations in the cfDNA of 1033 unselected advanced NSCLC patients at
presentation … Patients tested could not be biopsied, or the amount of cancer cells in biopsies or …